Foghorn Therapeutics Inc (FHTX)

Etorro trading 970x250
Foghorn Therapeutics Inc (FHTX) Logo

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139

Foghorn Therapeutics Inc News and around…

Latest news about Foghorn Therapeutics Inc (FHTX) common stock and company :

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) insider upped their holding by 2.2% earlier this year
20 Sep, 2021 Yahoo! Finance

Viewing insider transactions for Foghorn Therapeutics Inc.'s ( NASDAQ:FHTX ) over the last year, we see that insiders...

Bullish Two Hundred Day Moving Average Cross - FHTX
07 Sep, 2021 FinancialContent

In trading on Tuesday, shares of Foghorn Therapeutics Inc (FHTX) crossed above their 200 day moving average of $13.89, changing hands as high as $13.90 per share. Foghorn Therapeutics Inc shares are currently trading off about 2.8% on the day..

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
01 Sep, 2021 FinancialContent
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
23 Aug, 2021 FinancialContent
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
10 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

How The Pieces Add Up: IWN Targets $189
04 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $188.56 per unit.

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
03 Aug, 2021 FinancialContent

On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands ...

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
03 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
28 Jul, 2021 Yahoo! Finance

In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. If you want to skip our detailed analysis of Simons’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean […]

Could The Foghorn Therapeutics Inc. (NASDAQ:FHTX) Ownership Structure Tell Us Something Useful?
22 Jul, 2021 Yahoo! Finance

A look at the shareholders of Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) can tell us which group is most powerful. Large...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
14 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
09 Jul, 2021 FinancialContent
Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
08 Jun, 2021 FinancialContent
Foghorn Therapeutics to Present in Two Upcoming Investor Conferences
26 May, 2021 FinancialContent
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
25 May, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.

The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
21 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
20 May, 2021 FinancialContent

Before 10 a.m. ET Thursday, 8 stocks made new 52-week lows. Areas of Interest: The largest company in terms ...

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
20 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
19 May, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today an agreement with the world-renowned Fundecitrus, Fund for Citrus Protection, located in Araraquara, Brazil. The agreement focuses on the collaboration to evaluate the use of a novel natural peptide to control the devastating disease Citrus Greening (HLB) in Brazilian citrus trees.

The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
18 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
17 May, 2021 FinancialContent
Foghorn Therapeutics is Now Oversold (FHTX)
14 May, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
14 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Foghorn Therapeutics Provides Corporate Update
11 May, 2021 FinancialContent

Foghorn Therapeutics Inc (FHTX) is a NASDAQ Common Stock listed in , ,

970x250